A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)

Inclusion Criteria: 1. Signed written informed consent prior to any study procedures (patient and/or parent or legal guardian); 2. Gender is not limited, and the age at the time of screening is ≥ 18 years old and ≤ 65 years old; 3. Relapsed or refractory acute lymphoblastic leukemia (ALL); 4. Documentation of CD19 and/orCD22 tumor expression demonstrated in bone marrow or peripheral blood within 3 months before screening; 5. Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening; 6. ECOG score 0-1 points; 7. Organ function requirements: All patients must have adequate renal and liver functions. Exclusion Criteria: 1. Active Central Nervous System (CNS) involvement by malignancy; 2. Isolated extra-medullary disease relapse; 3. Patients with Burkitt's lymphoma/leukemia; 4. History of concomitant genetic syndrome; 5. Patients with acute graft-versus-host disease (GVHD) or moderate-tosevere chronic GVHD within 4 weeks before screening; Patients with a history of allogeneic hematopoietic stem cell transplantation within 12 weeks before single collection; 6. Active systemic autoimmune disease; 7. Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HbsAg positive) or hepatitis C virus (anti- HCV positive); 8. Patients with active infections at screening; 9. Patients who have used CAR-T cell therapy before screening; 10. Patients with an expected lifespan of less than 3 months.